Article Figures & Data
Figures
- Figure MRI Images
(A-B) T2/FLAIR images demonstrate subtle temporal and insular hyperintensities (arrows). (C-D) T2/FLAIR sequences six months posttreatment. Accounting for differences in technique, the subtle asymmetries on initial MRI are less apparent.
Tables
A Case Report
- Elizabeth Matthews, MD,
- Barrie Schmitt, MD,
- Michlene Passeri, MD,
- Christopher Mizenko, MS,
- Karen Orjuela, MD and
- Amanda Piquet, MD
- Correspondence
Dr. Matthews elizabeth.2.matthews{at}cuanschutz.edu
Abstract
Objective To report a case of α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor encephalitis (AMPARE) as a potential immune-mediated complication of palbociclib (a cyclin-dependent kinase 4/6 inhibitor).
Background Medication-induced autoimmune encephalitis is an increasingly recognized entity. To date, cases have been reported with immune checkpoint inhibitors (ICIs), typically within 3 months and while cancer is responding to immunotherapy.
Results A 55-year-old woman with metastatic breast cancer presented with new-onset neurologic symptoms. After diagnosis and treatment in 2008, she was in remission from 2010 to 2021. In April 2021, she developed metastatic recurrence. She started palbociclib in June 2021. PET scan in August 2021 showed improved metastases without new lesions. In September 2021, she developed encephalopathy, vertical nystagmus, and ataxia. Workup revealed AMPA-R antibodies. Palbociclib was stopped, and she received steroids, IVIg, and rituximab with marked improvement in her neurologic symptoms.
Discussion AMPARE is a well-described paraneoplastic syndrome. However, it is now understood that paraneoplastic syndromes can be driven by immunomodulatory medications, namely ICIs. Although palbociclib primarily prevents tumor proliferation, emerging data suggest that it may also be immunomodulatory. Given that our patient's AMPARE developed shortly after initiation of palbociclib while her cancer was responding to therapy, we postulate that it may have been unmasked by palbociclib, similarly to what has been reported with ICIs.
Glossary
- AIE=
- autoimmune encephalitis;
- AMPA-R=
- α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor;
- AMPARE=
- α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor encephalitis;
- CDK=
- cyclin-dependent kinase;
- ICI=
- immune checkpoint inhibitor;
- irAE=
- immune-related adverse event
It is increasingly recognized that autoimmune encephalitis (AIE) may be induced or unmasked by immunomodulatory medications. To date, cases have been reported with immune checkpoint inhibitors (ICIs).1 Palbociclib is a cyclin-dependent kinase 4/6 (CDK4/6) inhibitor, which primarily works by arresting tumor cells from entering the G1 cell cycle phase, as opposed to through immune system activation.2,3 However, there is growing evidence that palbociclib may have previously unrecognized immunomodulatory effects and thus may also carry the risk of immune-related adverse events (irAEs).2,3 We present a case of possible palbociclib-mediated AIE.
Case Report
A 55-year-old woman with metastatic breast cancer presented with new-onset neurologic symptoms. She initially developed breast cancer in 2008 (ER+/PR+/HER2−, treated with lumpectomy, radiation, and tamoxifen), followed by contralateral breast cancer in 2009 (ER+/PR+/HER2+, treated with lumpectomy, chemotherapy [docetaxel/carboplatin/cyclophosphamide/trastuzumab], and hormonal therapy). She had no evidence of disease from 2010 until April 2021, when she developed facial swelling and was found to have bone and lymph node metastases. She received radiation from April 2021 to June 2021 and started palbociclib in June 2021. A PET scan in August 2021 showed improvement in her metastases without new lesions. In September 2021, she developed confusion, blurry vision, vertical nystagmus, ataxia, constipation, and urinary retention. MRIs are shown in the Figure. CSF showed a lymphocytic pleocytosis, and antibody evaluations (Mayo Clinic) revealed serum and CSF α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor (AMPA-R) antibodies. She was switched from palbociclib to capecitabine and treated with steroids, IV immunoglobulin, and rituximab with marked improvement in her neurologic symptoms. At neurology follow-up, she had complete resolution of her nystagmus and ataxia and markedly improved cognitive (Montreal Cognitive Assessment was 8/30 during her admission, 27/30 at 2-month follow-up, and 29/30 at 6-month follow-up). Her cancer remains stable on capecitabine.
(A-B) T2/FLAIR images demonstrate subtle temporal and insular hyperintensities (arrows). (C-D) T2/FLAIR sequences six months posttreatment. Accounting for differences in technique, the subtle asymmetries on initial MRI are less apparent.
Discussion
AMPA-R encephalitis has been well described as a paraneoplastic syndrome associated with breast (among other) cancers.4 However, it is increasingly recognized that paraneoplastic syndromes may be driven or unmasked by medications, notably ICIs.5
The mechanism behind ICI-associated encephalitis is quite logical. By inhibiting regulatory immune checkpoints, ICIs lead to increased antitumor immunity. However, this effect nonspecific, and unregulated immune activity can affect nearly every organ system, leading to a variety of irAEs. This can include exacerbation of underlying immunologic conditions unrelated to the cancer or can present as tumor antigen-driven paraneoplastic syndromes that are unmasked when exposed to ICIs—which has been demonstrated eloquently in mouse models.1 When this unmasking occurs, the majority of cases occur within 3 months of ICI therapy.
Palbociclib has not historically been considered immunomodulatory. It is a CDK4/6 inhibitor, which primarily works by arresting tumor cells from entering the G1 cell cycle phase, thus preventing tumor proliferation. However, emerging data suggest that palbociclib may have significant immunomodulatory effects as well.2,3 T regulatory cells are particularly dependent on CDK4/6 for proliferation and are disproportionately depleted compared with T effector cells, tipping the immune system balance toward autoimmunity.3 Preclinical studies have shown that palbociclib also increases tumor antigen presentation and enhances cytotoxic T-cell activity.6,7 A similar phenomenon has been described with cyclophosphamide; at low doses, it preferentially depletes T regulatory cells and increases cytotoxic T-cell activity, leading to enhanced antitumor immunity.8
In addition to preclinical studies, there is growing real-world evidence that palbociclib may have both beneficial and detrimental immunomodulatory effects. A combined analysis of 2 phase I clinical trials suggests that clinical response to palbociclib in combination with ICIs is driven by immune priming by palbociclib.9 Palbociclib has also been associated with multiple systemic complications, a number of which are known to be immune mediated. Reports have included palbociclib-induced pneumonitis, hepatitis, nephritis, alopecia, vitiligo-like lesions, vasculitis, cutaneous lupus erythematosus, and Sweet syndrome.10,-,14 Many of these cases improved with discontinuation of palbociclib plus corticosteroids.
Although it is possible that our patient's AMPA-R encephalitis was purely due to her underlying malignancy, her neurologic symptoms developed while her cancer was responding clinically and radiographically to treatment, whereas paraneoplastic syndromes are often described in the setting of tumor progression or recurrence.15,16 Conversely, ICI-associated AIE is more likely to occur when cancer is responding to therapy.1,5 Given that palbociclib has a distinct mechanism to ICIs, it is difficult to directly compare their complications. However, it does make plausible sense that successful antitumor activity and detrimental autoimmunity would be likely to co-occur due to an overall robust immune response to palbociclib. Based on this biologic plausibility, the timing of our patient's presentation, the state of her cancer, and her rapid recovery after discontinuation of palbociclib and initiation of immunotherapy, we postulate that palbociclib may have induced or unmasked her AMPA-R encephalitis.
Study Funding
No targeted funding reported.
Disclosure
A.L. Piquet has received research funding from the University of Colorado and Rocky Mountain MS Center, consulting fees from Genentech/Roche and Alexion, honorarium from MedLink, and publication royalties from Springer. E.A. Matthews, B. Schmitt, M.R. Passeri, C. Mizenko, and K.D. Orjuela report no disclosures. Go to Neurology.org/NN for full disclosures.
Acknowledgment
The authors acknowledge the patient and her family for consenting to the publication of this case report, as well as the University of Colorado oncology team for their collaboration in this patient's care.
Appendix Authors
Footnotes
The Article Processing Charge was funded by the authors.
Go to Neurology.org/NN for full disclosures. Funding information is provided at the end of the article.
- Received January 28, 2022.
- Accepted in final form May 17, 2022.
- Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.
This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.
References
Letters: Rapid online correspondence
REQUIREMENTS
If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
